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ABSTRACT
We investigate parameter heterogeneity in breast cancer 1-year cumulative hospital costs across ﬁve European countries as
part of the EuroHOPE project. The paper aims to explore whether conditional mean effects provide a suitable representation
of the national variation in hospital costs. A cohort of patients with a primary diagnosis of invasive breast cancer (ICD-9
codes 174 and ICD-10 C50 codes) is derived using routinely collected individual breast cancer data from Finland, the met-
ropolitan area of Turin (Italy), Norway, Scotland and Sweden. Conditional mean effects are estimated by ordinary least
squares for each country, and quantile regressions are used to explore heterogeneity across the conditional quantile distri-
bution. Point estimates based on conditional mean effects provide a good approximation of treatment response for some
key demographic and diagnostic speciﬁc variables (e.g. age and ICD-10 diagnosis) across the conditional quantile distribu-
tion. For many policy variables of interest, however, there is considerable evidence of parameter heterogeneity that is
concealed if decisions are based solely on conditional mean results. The use of quantile regression methods reinforce the
need to consider beyond an average effect given the greater recognition that breast cancer is a complex disease reﬂecting
patient heterogeneity. Copyright © 2015 John Wiley & Sons, Ltd.
Received 28 January 2015; Revised 7 September 2015; Accepted 17 September 2015
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1. INTRODUCTION
There has been a persistent increase in the rate of incidence of breast cancer across many European countries
over the last 30 years (Bray et al., 2004; Ferlay et al., 2013). Although national breast cancer screening initia-
tives temporarily inﬂated rates by diagnosing a cohort of patients previously undetected, there remained a
general trend towards an average annual increase of 1–2% across many European countries for much of this
period (Berrino et al., 2007; Hery et al., 2008a; Hery et al., 2008b; Westlake and Cooper, 2008). A primary
concern for clinical decision making and resource allocation decisions relates to the greater demand on hospital
services. Health service and system responses have focused upon the priority setting of effective healthcare
*Correspondence to: Health Economics Research Centre, Nufﬁeld Department of Population Health, University of Oxford, Old Road
Campus, Oxford OX3 7LF, UK. E-mail: Joel.Smith@dph.ox.ac.uk
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treatments and technologies. Productivity and efﬁciency in which services are delivered remain a signiﬁcant
policy concern whilst striving to maximise population health outcomes. One consequence of the renewed
policy focus on productivity and efﬁciency gains is that the average length of stay for post-operative breast
cancer has been reduced in some European countries (Marla et al., 2013). It is unclear whether there are any
changes in breast cancer resource use because of the greater demand from increasing incidence or whether this
is offset by shorter length of stay.
There is greater recognition that breast cancer is a complex disease, and this has had a direct impact on the
changing nature of treatments. Whole-genome sequencing and other technological advancements in breast
cancer screening have changed the clinical pathway for many patients (Polyak, 2011). The treatment pathway
for a representative, or average, patient has been displaced by clinical evidence, which explicitly accommodates
the heterogeneity among breast cancer patients, prognoses and outcomes. Analysis of breast cancer resource
use should reﬂect the individualised approach to treatment in order to offer more pertinent health policy
insights.
The EuroHOPE project aims to investigate healthcare outcomes, performance and efﬁciency across
seven European countries for ﬁve health conditions. Using routine individual level breast cancer data from
Finland, the metropolitan area of Turin (Italy), Norway, Scotland and Sweden, this paper is concerned
with parameter heterogeneity in the cumulative hospital costs distribution. The key aim will be to explore
whether conditional mean effects provide a suitable representation of the national variation in hospital
costs whilst conﬁning the analysis to variables that are routinely recorded in administrative hospital
databases.
2. ECONOMETRIC SPECIFICATION
One-year cumulative hospital costs are used as a surrogate measure of breast cancer patient resource use.
Econometric analysis of cost data has been extensively applied in empirical research, and the methodolog-
ical challenges in terms of estimation are, therefore, well documented (for example, Mullahy, 1998;
Manning and Mullahy, 2001; Nixon and Thompson, 2004; Jones, Lomas and Rice, 2014). Much of this
literature is concerned with the analysis of costs within trial-based economic evaluations. Within this setting,
interest is conﬁned to inferences about the population mean cost in the presence of skewed cost distribu-
tions. The econometric analysis of cost within this paper differs in two important regards. Firstly, data shar-
ing restrictions among some of the EuroHOPE partner countries ruled out the pooling of data and conﬁned
analysis to remote access. Secondly, there is uncertainty regarding whether conditional mean effects are the
most salient message given policy interest is often focused upon the tails of the distribution in terms of
extreme costs or outliers. To address both of these points, a ﬂexible approach to the econometric analysis
of cost data is adopted in which no prior assumption is made regarding location scale and shape effects
for each EuroHOPE country.
Ordinary least squares (OLS) regression models are used to estimate conditional mean effects for the 1-year
cumulative hospital costs for each country. As cost data are commonly characterised by a long right-hand tail, a
natural log transformation was undertaken for all cost data prior to analysis to address this distributional feature.
Our linear regression model for the conditional mean is
Ln Costið Þ ¼ αþ β1di þ β2pi þ ui
where Costi is the 1-year cumulative hospital cost of patient i. di is a vector of demographic and diagnosis-
speciﬁc variables, including patient age, ICD-10 diagnosis and breast cancer severity as measured by stage.
pi is a vector of process variables, such as number of hospital procedures performed, length of stay in the
previous year of diagnosis, whether the patient was treated in a university/teaching hospital and a dummy
variable for patient mortality. No country-speciﬁc dummy variables are included as each regression is run
separately for each country due to data sharing restrictions.
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By extension, the quantile regression model for the conditional quantiles is
QCosti τ xiÞ ¼ α τð Þ þ β1xi τð Þ þ ui τð Þjð
where x is a vector including demographic and diagnosis speciﬁc, di, and process variables, pi. The quantile of
interest is estimated for each τ ∈ (0, 1) (Koenker and Hallock, 2001; Koenker, 2005).
3. DATA
We use routinely collected individual breast cancer data from ﬁve European countries to derive a cohort of
patients using a predeﬁned methodology across EuroHOPE partners (Douglas, 2012). The data source regis-
tries include patient records on every breast cancer diagnosis. We focus on those patients with a primary diag-
nosis of invasive breast cancer (ICD-9 codes 174 and ICD-10 C50 codes) in the ﬁnancial year 2005, with the
exception of Norway which uses 2009 data.1 Each individual record contains data on both demographic (age
and gender) and clinical variables (stage and diagnosis and number of procedures performed) as well as linked
data on administrative variables of interest (e.g. hospital type). Cumulative hospital costs cover the period from
admission to 1 year follow-up using linked hospital discharge data as well as death and cancer registers. Only
Finland, Norway and Sweden were able to include prescription data in the calculation of cumulative hospital
costs. Using the predeﬁned methodology, each country excluded patients that were either male or under
25 years of age at presentation and had recurrence of breast cancer of same histology/laterality that was ﬁrst
diagnosed before the start of data collection. In addition, only patients with complete hospital identiﬁcation
numbers were included in the study.
Aas (2012) outlines the episode-based costing methodology adopted by each EuroHOPE country. The ﬁrst hos-
pital episode for breast cancer is deﬁned as the ﬁrst hospital inpatient record following a diagnosis of breast cancer
using the relevant ICD-9/ICD-10 codes. Cumulative hospital costs are deﬁned as any patient breast cancer resource
use as an inpatient, day patient or outpatient up to 1 year after the recorded date of diagnosis of breast cancer. This
includes surgical and non-surgical treatments, such as chemotherapy, radiotherapy and hormone therapy, with the
exception of Norway, which were unable to include hormone therapy. Hospital inpatient, including day surgery, is
classiﬁed by diagnosis-related groups for all countries with the exception of Scotland, which is based on healthcare
resource groups for all inpatient activity. Fee-based mechanisms are assigned to all outpatient visits and prescrib-
ing data, where available. Costs for all countries have been converted to 2011 UK pound sterling (£s)2 using
Organisation for Economic Co-operation and Development (OECD) purchasing power parities (OECD, 2012).
Although Hungary and the Netherlands are also participating in the wider EuroHOPE project, neither country
supplied data for the breast cancer cost analysis reported in this paper. The Netherlands did not contribute data
for the breast cancer analysis as it was not possible to link patient records from the National cancer register to hos-
pital discharge records. Hungary was only able to provide data on length of stay due to difﬁculties in record linkage
to discharge registers needed to calculate hospital costs. The sample for the cost analysis is, therefore, conﬁned to
Finland, the metropolitan area of Turin (Italy), Norway, Scotland and Sweden.
One-year cumulative log hospital costs represent the dependent variable in all regression models. Indepen-
dent variables include patient characteristics such as breast cancer stage, ICD-10 diagnosis, mortality, hospital
length of stay in the year prior to the breast cancer diagnosis, age in years and a quadratic function for age to
accommodate non-linear relationships. Dummy variables are used to control for differing ICD-10 diagnoses as
well as a separate variable to capture patient mortality using survival as the reference category (e.g. survival = 0;
died = 1 based on the date of death with follow-up up to December 2010 for all countries except Finland who
1Data from 2009 for Norway was used as it was not possible to link data on resource use to patient records before 2008 (the year prior to the
index admission of 2009).
2The interpretation and magnitude of the coefﬁcients reported in the regression analyses remain the same for other currencies, such as the
euro (€), with the exception of the intercept which will be sensitive to the currency selected.
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had follow-up up to December 2011). Breast cancer stage is used as a measure of severity using stage 1 as the
reference category. The number of days spent in hospital in the previous year prior to diagnosis is used as a
proxy for comorbidities in addition to the mortality dummy variable. We also control for the number of proce-
dures performed to account for the possibility of variation in treatment pathways depending on hospital type
and locality. Hospital type is included as a dummy variable to estimate whether there are differences between
university teaching hospitals/specialist breast cancer centres relative to other hospitals in terms of length of stay
and costs.
4. RESULTS
Table I presents the summary statistics for the key variables. A comparison of the mean and standard deviation
for the length of stay variable illustrates the variation in the patterns of breast cancer care across countries.
Despite the use of a predeﬁned methodology for data collection and analysis for the EuroHOPE project, Table I
Table I. Descriptive statistics for the key variables of interest for Finland, Italy, Norway, Scotland and Sweden
Mean Std. Dev. Min. Max. N
Finland
Length of stay (LoS) 6.1 19.8 1 365 3200
Year 1 costs (UK £) 9788 6827 341 136996 3200
Age (years) 61.9 13.1 27 98 3943
LoSt1 0.38 3.3 0 118 3943
Mortality dummy 0.23 0.42 0 1 3943
No. of procedures 1.2 0.9 0 4 3943
Hospital dummy 0.30 0.46 0 1 3943
Italy
Length of stay (LoS) 4.7 7.3 1 153 680
Year 1 costs (UK £) 10348 17934 0 311036 778
Age (years) 63.5 14.1 29 94 778
LoSt1 0.10 0.8 0 12 778
Mortality dummy 0.21 0.41 0 1 779
No. of procedures 0.9 0.5 0 3 779
Norway
Length of stay (LoS) 2.9 4.6 1 130 2804
Year 1 costs (UK £) 34293 22747 0 255546 2790
Age (years) 62.2 14.0 26 98 2816
LoSt1 2.92 9.2 0 185 2816
Mortality dummy 0.07 0.26 0 1 2816
No. of procedures 1.3 0.8 0 4 2816
Scotland
Length of stay (LoS) 6.3 14.0 1 365 3427
Year 1 costs (UK £) 15822 13183 886 137660 3542
Age (years) 63.1 14.5 25 102 3963
LoSt1 1.83 10.6 0 243 3963
Mortality dummy 0.33 0.47 0 1 3963
No. of procedures 0.9 0.5 0 3 3963
Hospital dummy 0.52 0.50 0 1 3427
Sweden
Length of stay (LoS) 4.0 6.1 1 272 5896
Year 1 costs (UK £) 6917 4640 204 76507 6782
Age (years) 63.4 13.9 25 101 7164
LoSt1 0.19 1.4 0 48 7164
Mortality dummy 0.22 0.41 0 1 7164
No. of procedures 0.9 0.5 0 3 7164
LoS = ﬁrst hospital episode; LoSt1 = length of stay in the previous year; Mortality = patient mortality dummy variable; No. of
procedures = number of procedures performed; Hospital dummy = dummy variable for whether the patient was treated in a university teach-
ing hospital or specialist breast cancer centre.
J. SMITH ET AL.26
Copyright © 2015 John Wiley & Sons, Ltd. Health Econ. 24(Suppl. 2): 23–37 (2015)
DOI: 10.1002/hec
illustrates that some variables do not appear to be directly comparable across countries. The magnitude of some
of the differences across countries may simply be a manifestation of registry data access or quality and, there-
fore, observed differences may be spurious. Notable examples outlined in Table I include the mortality dummy
variable for Norway and the costs estimates across all countries, which include a mixture of diagnosis-related
groups (Finland, Italy, Norway and Sweden) and healthcare resource group (Scotland) episode-based costing
methodologies. To minimise spurious conclusions, interpretation of all results presented should focus on
national parameter heterogeneity rather than cross-country comparisons.
The distribution of 1-year hospital costs by country is presented in Figure 1. As illustrated, the cost distri-
butions across countries are skewed with a long right-hand tail.
Table II presents the estimated coefﬁcients from the OLS regression model for the 1-year cumulative
hospital costs for each country. The national conditional mean effects for Finland are reported in column (1).
Cost estimates for patients diagnosed using ICD-10 code C508 (overlapping lesion of breast) are 11% lower,
on average, relative to the reference category of ICD-10 code C500 (nipple and areola). For patients classiﬁed
with stage 2 breast cancer, estimated costs are 25% higher relative to stage 1 patients. This rises to a 38% and
31% increase in costs for stage 3 and 4 patients, respectively, compared with stage 1. The proxy for comorbid-
ities in Finland results in a 3% increase in costs for each additional day spent in hospital in the previous year.
Patient mortality is associated with an 11% increase in 1-year hospital costs relative to patients that survived.
Figures 2–6 present the conditional mean and conditional quantile results for each country. The quantile
regression results are used to explore evidence of parameter heterogeneity around the conditional mean effect
reported in Table II. Each ﬁgure is constructed with the conditional mean effect represented by the thick black
Figure 1. Kernel density of the 1-year cumulative hospital costs for Finland, Italy, Norway, Scotland and Sweden
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dashed line with corresponding 95% conﬁdence interval denoted by the upper and lower dotted lines. Hetero-
geneity in the response of covariates for breast cancer costs across conditional quantiles is represented by the
thick solid line, and the grey shaded area denotes the corresponding uncertainty in terms of the quantile conﬁ-
dence interval. If the conditional quantile effect exceeds the bounds of the OLS conﬁdence interval, then this
provides support for parameter heterogeneity. To supplement Figures 2–6, the coefﬁcients and standard errors
for the quantile regression model results at the median; lower and upper quartile are presented in Tables S3–S7
in the Supporting Information.
Figure 2 presents the conditional mean and conditional quantile results for Finland. There is evidence of
treatment response heterogeneity across the conditional quantiles. There is a 13% increase in the costs for
patients diagnosed using ICD-10 code C504 (upper-outer quadrant of breast) at the lower conditional quartile
but no signiﬁcant differences at the conditional mean, median or upper quartile. The conditional mean effect for
stage 2 patients provides a good approximation of the relative increase in costs compared with stage 1 patients
across conditional quantiles. In contrast, the conditional mean effect for stage 3 patients masks response hetero-
geneity across the conditional quantiles. For example, the costs for stage 3 patients are estimated to be 43%
higher at the lower conditional quartile, 32% higher at the upper quartile and 38% higher, on average, relative
to stage 1 patients. Hospital costs for stage 4 patients are estimated to be 24% higher at the lower conditional
quartile, 40% higher at the median and 31% higher for both the conditional mean and upper conditional quartile
relative to stage 1 patients. Although the conditional mean effect for the comorbidity variable estimates each
Figure 2. A comparison of the conditional mean (represented by the thick black dashed line with corresponding 95% conﬁdence interval
denoted by the upper and lower dotted lines) and the conditional quantile effects (denoted by the thick solid line and the grey shaded area
corresponding to the quantile conﬁdence interval) for 1-year cumulative hospital costs for Finland
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additional day spent in hospital in the previous year to increase costs by 3%, conditional median results suggest
each day is associated with a 2% increase and upper quartile estimates consider an increases in costs of 4% per
day in the previous year. Patient mortality is associated with a 7% increase in 1-year hospital costs at the
conditional median, 20% increase in costs at the upper quartile but the estimated coefﬁcient is not signiﬁcant
at the lower conditional quartile relative to patients that survived. The number of breast cancer procedures
performed is not signiﬁcant at any conventional level for both the conditional median and lower quartile.
However, the sign and magnitude of the coefﬁcients change between the lower and upper quartile with the
upper conditional quartile estimating each additional procedure performed to increase hospital costs by 5%.
Column (2) in Table II reports the estimated coefﬁcients for the OLS cost regression model for the metro-
politan area of Turin (Italy). Cost estimates for breast cancer stage monotonically increase with the level of
severity. For patients classiﬁed with stage 2 breast cancer, estimated costs are 24% higher relative to stage 1
patients. This rises to a 78% and 151% increase in costs for stage 3 and 4 patients, respectively, compared with
stage 1. Each additional breast cancer procedure performed in hospitals in Italy is estimated, on average, to
increase costs by 32%. The conditional mean and conditional quantile results for Italy are presented in Figure 3.
As illustrated in Figure 3, the conditional mean effect for all breast cancer stage variables provides a good
approximation of the relative increase in costs compared with stage 1 patients across conditional quantiles.
In contrast, there is evidence of parameter heterogeneity for both the number of procedures performed and
hospital type across conditional quantiles. The number of breast cancer procedures performed is not signiﬁcant
Figure 3. A comparison of the conditional mean (represented by the thick black dashed line with corresponding 95% conﬁdence interval
denoted by the upper and lower dotted lines) and the conditional quantile effects (denoted by the thick solid line and the grey shaded area
corresponding to the quantile conﬁdence interval) for 1-year cumulative hospital costs for Italy
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at the upper quartile. However, costs are increased by 32% for each additional breast cancer procedure
performed at the conditional mean and median as well as a 39% increase in costs at the lower quartile. The costs
for patients treated in university teaching hospitals or specialist breast cancer centres in Italy is not signiﬁcant at
any conventional level at the conditional mean, median or lower quartile. In contrast, patients treated in univer-
sity teaching hospitals or specialist breast cancer centres at the upper conditional quartile is estimated to reduce
costs by 25% relative to other hospital types.
The estimated coefﬁcients from the Norway OLS regression model for 1-year cumulative hospital costs are
presented in column (3) of Table II. For patients classiﬁed with stage 2 and stage 4 breast cancer, estimated
costs are 26% higher relative to stage 1 patients. This rises to a 55% increase for stage 3 patients compared with
stage 1. The proxy for comorbidities in Norway results in a 0.7% increase in costs for each additional day spent
in hospital in the previous year. Patient mortality is associated with a 14% increase in 1-year hospital costs
relative to patients that survived. Each additional breast cancer procedure performed in hospitals in Norway
is estimated, on average, to reduce costs by 7%. Furthermore, the costs for patients treated in university teach-
ing hospitals or specialist breast cancer centres in Norway is estimated to be 7% lower relative to other hospital
types.
Figure 4 presents the conditional mean and conditional quantile results for Norway. The conditional mean
effect for stage 3 patients provides a good approximation of the relative increase in costs compared with stage
1 patients across conditional quantiles. In contrast, the average treatment response based on the OLS regression
Figure 4. A comparison of the conditional mean (represented by the thick black dashed line with corresponding 95% conﬁdence interval
denoted by the upper and lower dotted lines) and the conditional quantile effects (denoted by the thick solid line and the grey shaded area
corresponding to the quantile conﬁdence interval) for 1-year cumulative hospital costs for Norway
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model for stage 2 and stage 4 patients fails to uncover important heterogeneity across the conditional quantiles.
For example, the costs for stage 2 patients are estimated to be 22% higher at the lower conditional quartile, 32%
higher at the upper quartile and 26% higher, on average, relative to stage 1 patients. The costs for stage 4
patients are not signiﬁcant at the lower quartile but are estimated to be 28% higher at the median, 41% higher
at the upper conditional quartile and 26% higher at the conditional mean relative to stage 1 patients. Although
the conditional mean response is the same for both stage 2 and stage 4 patients, there is a greater variation in the
most severe breast cancer category represented by stage 4. The comorbidity variable estimates each additional
day in hospital in the previous year to increase costs by 0.7% for the conditional mean, 1% for conditional
median and 1.4% at the upper conditional quartile. Patient mortality is associated with a 20% increase in 1-year
hospital costs at the conditional median and 24% increase in costs at the upper quartile, but the estimated
coefﬁcient is not signiﬁcant at the lower conditional quartile relative to patients that survived. The number
of breast cancer procedures performed is not signiﬁcant at the upper quartile. However, costs are reduced by
9% for each additional procedure performed at the median, reduced by 19% at the lower quartile, whilst the
conditional mean effect reported a reduction of 7%. The costs for patients treated in university teaching hospi-
tals or specialist breast cancer centres in Norway is estimated to be 6% lower at the conditional median and this
increases to a reduction in costs by 14% at the lower quartile relative to other hospital types.
Column (4) in Table II reports the estimated coefﬁcients for the cost regression model for Scotland. For
patients classiﬁed with stage 2, 3 or 4 breast cancers, the estimated costs are 52%, 68% and 55% higher,
Figure 5. A comparison of the conditional mean (represented by the thick black dashed line with corresponding 95% conﬁdence interval
denoted by the upper and lower dotted lines) and the conditional quantile effects (denoted by the thick solid line and the grey shaded area
corresponding to the quantile conﬁdence interval) for 1-year cumulative hospital costs for Scotland
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respectively, relative to stage 1 patients. Patient mortality is associated with a 16% increase in 1-year hospital
costs relative to patients that survived. Each additional breast cancer procedure performed in hospitals in
Scotland is estimated, on average, to increase costs by 28%. Figure 5 presents the conditional mean and
conditional quantile results for Scotland. There is evidence of treatment response heterogeneity across the
conditional quantiles. There is a 31% and 32% reduction in costs for patients diagnosed using ICD-10 codes
C503 (lower-inner quadrant of breast) and C506 (axillary tail of breast) at the lower conditional quartile but
no signiﬁcant differences at the conditional mean, median or upper quartile. The conditional mean effect for
all breast cancer staging variables does not provide a good approximation of the relative increase in costs
compared with stage 1 patients. One-year hospital costs for stage 2 patients are estimated to be 57% higher
at the lower conditional quartile, 60% higher at the median and 49% higher at the upper conditional quartile
relative to stage 1 patients. Costs for stage 3 patients are estimated to be 78% higher at the lower conditional
quartile, 77% higher at the median and 58% higher at the upper conditional quartile relative to stage 1 patients.
Hospital costs for stage 4 patients are estimated to be 54% higher at the lower conditional quartile, 61% higher
at the median and 56% higher for the upper conditional quartile relative to stage 1 patients. Patient mortality is
associated with a 15%, 19% and 16% increase in 1-year hospital costs at the lower conditional quartile, median
and upper conditional quartile relative to patients that survived. Hospital costs are increased by 43%, 30% and
17% for each additional breast cancer procedure performed in Scotland at the lower conditional quartile,
median and upper conditional quartile, respectively. Although hospital type is not signiﬁcant at the conditional
Figure 6. A comparison of the conditional mean (represented by the thick black dashed line with corresponding 95% conﬁdence interval
denoted by the upper and lower dotted lines) and the conditional quantile effects (denoted by the thick solid line and the grey shaded area
corresponding to the quantile conﬁdence interval) for 1-year cumulative hospital costs for Sweden
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mean or lower quartile, the costs for patients treated in university teaching hospitals or specialist breast cancer
centres in Scotland is estimated to be 7% lower at the conditional median and 9% lower at the upper quartile
relative to other hospital types.
The national conditional mean effects for Sweden for 1-year hospital costs based on the OLS regression
model are reported in column (5) of Table II. Cost estimates for breast cancer stage monotonically increase with
the level of severity. For patients classiﬁed with stage 2 breast cancer, estimated costs are 17% higher relative to
stage 1 patients. This rises to a 30% and 40% increase in costs for stage 3 and 4 patients, respectively, compared
with stage 1. The proxy for comorbidities in Sweden results in just under a 5% increase in costs for each
additional day spent in hospital in the previous year. Each additional breast cancer procedure performed in
hospitals in Sweden is estimated, on average, to increase costs by 63%.
Figure 6 presents the conditional mean and conditional quantile results for Sweden. The conditional mean
effect for all breast cancer staging variables does not provide a good approximation of the relative increase
in costs compared with stage 1 patients. One-year hospital costs for stage 2 patients are estimated to be 11%
higher at the lower conditional quartile, 14% higher at the median and 13% higher at the upper conditional
quartile relative to stage 1 patients. Costs for stage 3 patients are estimated to be 18% higher at the lower
conditional quartile, 24% higher at the median and 31% higher at the upper conditional quartile relative to stage
1 patients. Hospital costs for stage 4 patients are estimated to be 15% higher at the lower conditional quartile,
25% higher at the median and 40% higher for the upper conditional quartile relative to stage 1 patients. The
comorbidity variable estimates each additional day in hospital in the previous year to increase costs by just
under 5% for the conditional mean, just over 5% for conditional median, less than 2% at the lower quartile
and over 3.5% at the upper conditional quartile. Patient mortality is associated with a 5% increase in 1-year
hospital costs at the conditional median, 11% increase in costs at the upper quartile, but the estimated coefﬁ-
cient is not signiﬁcant at the lower conditional quartile or conditional mean relative to patients that survived.
Hospital costs are increased by 59%, 44% and 32% for each additional breast cancer procedure performed in
Sweden at the lower conditional quartile, median and upper conditional quartile, respectively.
5. DISCUSSION AND CONCLUDING REMARKS
This paper considers whether conditional mean effects provide a suitable representation of national data on
1-year breast cancer cumulative hospital costs. Point estimates based on conditional mean effects provide a
good approximation of treatment response for some key demographic and diagnostic-speciﬁc variables (e.g.
age and ICD-10 diagnosis) across the conditional quantile distribution. For many policy variables of inter-
est, however, there is a considerable evidence of parameter heterogeneity that is concealed if decisions are
based solely on conditional mean results. Mortality, breast cancer stage and hospital type are all important
variables in determining patient treatment, outcomes, access and service delivery. This paper has illustrated
that these key variables are also important for determining the location scale and shape of breast cancer
cumulative hospital costs over a 1-year period. Although there have been national policy initiatives to
reduce breast cancer length of stay, heterogeneity still exists. The quantile regression results reinforce the
need to consider beyond an average effect given the results of parameter heterogeneity.
A number of limitations exist in terms of the study design. Data sharing restrictions across EuroHOPE
countries imposed constraints in terms of analysis as the pooling of data was not feasible. Instead, the
EuroHOPE project relied on a common methodology across countries to ensure consistency in reporting and
analysis of national data as outlined by Douglas (2012). There remains a large proportion of missing data across
countries, particularly in terms of the variables used to derive breast cancer staging categories. The methodo-
logical challenges in terms of breast cancer staging in cross-country studies is well established, and potential
solutions have been proposed (e.g. Walters et al., 2013). Despite this literature, attempts to follow the recom-
mended guidelines did not address the challenges associated with imputing missing stage data. In particular, the
imputation of missing stage data following the approach by Walters et al. (2013) still resulted in around 50%
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missing stage data for both Finland and Sweden because of breast cancer stage coding discrepancies. The
reported results are, therefore, conﬁned to complete case analysis for all countries given the uncertainty in
the pattern of missingness across key variables. Statistical methods for addressing missing data, such as multi-
ple imputations by chained equations, are further inhibited by the data sharing restrictions across EuroHOPE
partner countries, large percentage of missing data for some key variables (i.e. breast cancer stage) as well
as uncertainty about whether the data are missing (not) at random. A number of countries were also constrained
in terms of linking data to other registries which resulted in certain covariates being excluded from regression
models as well as the loss of countries from the sample.3 Beral and Peto (2010) have previously raised concerns
about the quality of breast cancer registry data although Woods et al. (2011) posit a more optimistic outlook
through a simulation study of the National Cancer Registry data from England and Wales. In light of the meth-
odological challenges, caution is needed for the interpretation and generalisability of the regression results pre-
sented in this paper as part of the EuroHOPE project.
The costing methodology adopted by each EuroHOPE country relied on the best available data and
estimates. As a result, differences exist in terms of episode-based costing estimates with a mixture of
diagnosis-related groups as well as healthcare resource groups Geue et al. (2012) have previously demonstrated
the sensitivity of results to the costing methodology adopted. It is worth reiterating that the aim of the paper was
to explore parameter heterogeneity in national breast cancer cost data rather than cross-country disparities in
hospital costs. However, the difference in costing methodology across countries could explain some of the
differences in magnitude and sign for certain covariates included in the regression models. The number of
procedures performed changes in sign and magnitude across countries and may simply be a manifestation of
the underlying costing methodologies adopted. For this reason, interpretation should focus upon parameter
heterogeneity across conditional quantiles within countries rather than between EuroHOPE countries.
A common methodology was adopted for the EuroHOPE project in terms of model selection based on avail-
able data across all countries. Important covariates were included in the regression models to control for patient
case-mix and characteristics that may inﬂuence hospital costs. It was not possible to include a common measure
of socio-economic status across EuroHOPE countries, which may have an impact on study results. In addition,
there may be other forms of unobserved patient heterogeneity that the regression models are unable to accom-
modate. This may include patient frailty, engagement and treatment preferences which could bias results in
either direction in terms of LoS as well as hospital costs. For many forms of unobserved heterogeneity, there
is an inevitable interaction with observable characteristics. The use of quantile regression methods, in this
setting, becomes particularly salient as a means of exploring potential exogenous shifts in the regressors across
the conditional distribution (Miranda, 2008). One ﬁnal consideration relates to the presence of potential endog-
enous regressors in the model speciﬁcation, such as the mortality dummy variable. The methodological
challenges associated with the identiﬁcation of suitable instruments to address the endogeneity problem with
cross-sectional observational data are well established in the literature (Staiger and Stock, 1997). As a result,
a pragmatic approach was adopted by focusing on the OLS estimates in light of the absence of suitable instru-
ments collected in national breast cancer registers. Although tests for weak instruments are available for single
(Stock and Yogo, 2005) or multiple endogenous regressors (Sanderson and Windmeiejer, 2013), the conse-
quences of weak instruments can induce greater bias. In this setting, the cure to the endogeneity problem
can be worse than the diagnosis itself (Hahn and Hausman, 2003).
The direction of future research should focus upon the possible determinants of heterogeneity in outcomes
as well as treatment response across the conditional distribution. One important contribution to the literature
would be to consider the dependency between hospitals within countries in light of the heterogeneity reported
in this paper. Gravelle, Santos and Siciliani (2013) have recently demonstrated the signiﬁcance of spatial
dependence between hospitals in determining quality. Cross-country studies, such as EuroHOPE, need to
consider the appropriate spatial unit to capture any dependency between hospitals. For example, geographic,
3For example, information relating to the fourth digit of the ICD-10 diagnosis variable for Norway was not collated at the time of data
retrieval and, therefore, absent from the ﬁnal analysis dataset.
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administrative or health system units may all represent a clustering of outcomes in terms of healthcare perfor-
mance, quality and efﬁciency. Jones and Spiegelhalter (2011) acknowledge the methodological challenges in
the identiﬁcation of extreme hospital outcomes or outliers and offer possible strategies to overcome these
difﬁculties. The incorporation of national treatment guidelines with expert opinion from clinicians and
healthcare providers across all participating countries offers a fruitful means of benchmarking European
hospital outcomes prior to the analysis of data to identify extremes or outliers.
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